1)Katsumata N, et al : Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer : a phase 3, open-label, randomized controlled trial. Lancet 374 : 1331─1338, 2009
2)Burger RA, et al : Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365 : 2473─2483, 2011
3)Perren TJ, et al : A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365 : 2484─2496, 2011
4)Gonzalez-Martin A, et al : Efficacy and safety results from OCTAVVIA, a single-arm phase II evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Caner 49 : 3831─3838, 2013
5)Chan JK, et al : Weekly vs. every-3 week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 374 : 738─748, 2016
6)Klauber N, et al : Inhibition of angiogenesis and breast cancer in mice by the microtuble inhibitors 2-methoxyestradiol and taxol. Cancer Res 57 : 81─86, 1997
7)Pujade-Lauraine E, et al : Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cacer : The AURELIA open-label randomized phase III trial. J Clin Oncol 32 : 1302─1308, 2014
8)Miller K, et al : Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 : 2666─2676, 2007
9)Gourley C, et al : Molecular subgroup of high-grade serous ovarian cancer(HGSOC)as a predictor of outcome following bevacizumab. J Clin Oncol 32(15), 2014(suppl ; abstr 5502)
10)Birrer MJ, et al : Retrospective analysis of candidate predictive tumor biomarkers(BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin-paclitaxel(CP) ±bevacizumab(BEV) for epithelial ovarian cancer(EOC). J Clin Oncol 33, 2015(suppl ; abstr 5505)